My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 423

    1.

    A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

    Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators.

    Diabetes Care. 2005 Jul;28(7):1547-54.PMID: 15983299 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

    Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J.

    Clin Ther. 2002 Mar;24(3):378-96.PMID: 11952022 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    4.

    Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

    Olansky L, Marchetti A, Lau H.

    Clin Ther. 2003;25 Suppl B:B64-80. Review.PMID: 14553867 [PubMed - indexed for MEDLINE]Related articles

    5.

    The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

    Coron Artery Dis. 2001 Aug;12(5):413-23.PMID: 11491207 [PubMed - indexed for MEDLINE]Related articles

    6.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    7.

    Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.

    Am J Med. 2001 Jul;111(1):10-7.PMID: 11448655 [PubMed - indexed for MEDLINE]Related articles

    8.

    A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

    Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

    9.

    Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

    Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A; Rosiglitazone Clinical Trials Study Group.

    Diabetes Care. 2001 Feb;24(2):308-15. Erratum in: Diabetes Care 2001 May;24(5):973. PMID: 11213884 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.

    King AB, Armstrong DU.

    Diabetes Technol Ther. 2002;4(2):145-51.PMID: 12079617 [PubMed - indexed for MEDLINE]Related articles

    11.

    Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

    Patel J, Anderson RJ, Rappaport EB.

    Diabetes Obes Metab. 1999 May;1(3):165-72.PMID: 11220295 [PubMed - indexed for MEDLINE]Related articles

    12.

    Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.

    LaCivita KA, Villarreal G.

    Curr Med Res Opin. 2002;18(6):363-70.PMID: 12442884 [PubMed - indexed for MEDLINE]Related articles

    13.

    Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

    Miyazaki Y, DeFronzo RA.

    Diabetes Obes Metab. 2008 Dec;10(12):1204-11. Epub 2008 May 12.PMID: 18476983 [PubMed - indexed for MEDLINE]Related articles

    14.

    Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.

    Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H.

    Curr Med Res Opin. 2004;20(2):215-23.PMID: 15006017 [PubMed - indexed for MEDLINE]Related articles

    15.

    One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

    Diabetes Care. 2004 Jan;27(1):141-7.PMID: 14693980 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.

    Diabetes Care. 2006 May;29(5):1016-23.PMID: 16644631 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

    Chiquette E, Ramirez G, Defronzo R.

    Arch Intern Med. 2004 Oct 25;164(19):2097-104.PMID: 15505122 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.

    Dailey GE 3rd, Mohideen P, Fiedorek FT.

    Clin Ther. 2002 Sep;24(9):1426-38.PMID: 12380634 [PubMed - indexed for MEDLINE]Related articles

    19.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    20.

    Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.

    Diabetes Care. 2000 Nov;23(11):1605-11.PMID: 11092281 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity